Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Dealmaking Pays Off For Allergan As Revenue Rises 124% In 2015

This article was originally published in Scrip

Executive Summary

Allergan PLC's dealmaking ways paid off in 2015 as revenue rose 124% to $15.1bn and non-GAAP earnings per share grew 78% to $13.43, thanks in large part to Actavis PLC's $66bn acquisition of Botox (onabotulinumtoxinA) maker Allergan Inc. last year and other recent transactions.

Advertisement

Related Content

PhRMA Uses Allergan Stage In Campaign To Keep Focus On Industry's Reputation For Innovation

Topics

Advertisement
UsernamePublicRestriction

Register

SC064567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel